Janus Henderson Global Life Sciences A (JFNAX)

Fund Assets	6.03B
Expense Ratio	1.00%
Min. Investment	$2,500
Turnover	30.00%
Dividend (ttm)	0.26
Dividend Yield	0.31%
Dividend Growth	198.30%
Payout Frequency	Annual
Ex-Dividend Date	Dec 5, 2025

Previous Close	83.77
YTD Return	6.20%
1-Year Return	21.65%
5-Year Return	47.59%
52-Week Low	71.94
52-Week High	91.65
Beta (5Y)	0.79
Holdings	98
Inception Date	Jul 6, 2009

About JFNAX

Janus Henderson Global Life Sciences Fund Class A is an actively managed mutual fund specializing in the health and life sciences sector. Its principal objective is to achieve long-term capital growth by investing at least 80% of its assets in equities of companies engaged in biotechnology, pharmaceuticals, healthcare services, and medical devices on a global scale. The fund maintains a diversified portfolio, typically holding between 80 and 120 stocks, and includes both large and smaller capitalization firms. It aims to outperform the MSCI World Health Care Index by at least 2% per annum over any five-year period, before fees. The fund is managed by a dedicated team with expertise in both scientific and business aspects of healthcare, seeking to identify companies addressing unmet medical needs or advancing healthcare system efficiency. Up to 20% of assets may be allocated to emerging markets, and derivatives may be used for risk management or additional capital generation. The strategy is designed for investors seeking exposure to innovation and growth opportunities within the global life sciences industry while maintaining a balanced approach to sector allocation.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: High
• Risk Rating: Average
• Stock Exchange: Nasdaq
• Ticker Symbol: JFNAX
• Share Class: Class A
• Index: MSCI World/Health Care NR

Performance

JFNAX had a total return of 21.65% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.76%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JFNIX	Class I	0.78%
JNGLX	Class D	0.81%
JAGLX	Class T	0.92%

Top 10 Holdings

42.22% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	9.05%
Johnson & Johnson	JNJ	7.48%
AbbVie Inc.	ABBV	4.63%
UnitedHealth Group Incorporated	UNH	4.33%
AstraZeneca PLC	AZN	3.50%
Thermo Fisher Scientific Inc.	TMO	2.92%
Novartis AG ADR	NVSN.MX	2.78%
Roche Holding AG	ROP	2.63%
argenx SE	ARGX	2.55%
Abbott Laboratories	ABT	2.36%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 5, 2025	$3.59379	Dec 5, 2025
Dec 6, 2024	$3.8026	Dec 6, 2024
Dec 7, 2023	$2.86828	Dec 7, 2023
Dec 20, 2022	$0.04945	Dec 20, 2022
Dec 20, 2021	$6.7078	Dec 20, 2021
Dec 17, 2020	$5.47231	Dec 17, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 7, 2026

Data Sources Report a data error